Stockscreener 앱 받기
21.18
7.91%
-1.82
시간 외 거래:
21.17
-0.010
-0.05%
전일 마감가:
$23.00
열려 있는:
$21.75
하루 거래량:
533.82K
Relative Volume:
3.00
시가총액:
$583.36M
수익:
-
순이익/손실:
$-69.47M
주가수익비율:
-3.784
EPS:
-5.5973
순현금흐름:
$-73.92M
1주 성능:
-17.39%
1개월 성능:
-1.53%
6개월 성능:
-17.84%
1년 성능:
+0.00%
1일 변동 폭
$20.08
$22.02
1주일 범위
$20.08
$27.30
52주 변동 폭
$14.42
$38.93
Lenz Therapeutics Inc Stock (LENZ) Company Profile
명칭
Lenz Therapeutics Inc
전화
858-925-7000
주소
201 LOMAS SANTA FE DRIVE, SUITE 300, SOLANA BEACH
LENZ을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LENZ
Lenz Therapeutics Inc
|
21.18 | 583.36M | 0 | -69.47M | -73.92M | -5.5973 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Lenz Therapeutics Inc Stock (LENZ) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-18 | 개시 | TD Cowen | Buy |
| 2024-09-27 | 개시 | Raymond James | Outperform |
| 2024-08-12 | 개시 | H.C. Wainwright | Buy |
| 2024-04-15 | 개시 | Leerink Partners | Outperform |
| 2024-04-15 | 개시 | William Blair | Outperform |
| 2024-04-10 | 개시 | Citigroup | Buy |
| 2024-03-27 | 개시 | Piper Sandler | Overweight |
| 2023-02-23 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2023-02-23 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-02-23 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2023-01-25 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2023-01-18 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-01-06 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-06 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2022-09-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-06-17 | 개시 | BMO Capital Markets | Outperform |
| 2022-04-14 | 개시 | BTIG Research | Buy |
| 2022-03-22 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-02-18 | 개시 | RBC Capital Mkts | Sector Perform |
| 2021-07-20 | 개시 | Morgan Stanley | Overweight |
| 2021-07-20 | 개시 | SVB Leerink | Outperform |
모두보기
Lenz Therapeutics Inc 주식(LENZ)의 최신 뉴스
Presbyopia Treatment Market Size in 7MM is expected to grow at - openPR.com
18,900 Shares in LENZ Therapeutics, Inc. (NASDAQ:LENZ) Purchased by Swiss National Bank - Defense World
Swiss National Bank Takes $546,000 Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - MarketBeat
LENZ Therapeutics Stock Is Attractive Before PDUFA (NASDAQ:LENZ) - Seeking Alpha
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Shares Purchased by Charles Schwab Investment Management Inc. - Defense World
Bank of New York Mellon Corp Lowers Stock Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
Brokers Issue Forecasts for LENZ Q2 Earnings - Defense World
What is Leerink Partnrs’ Forecast for LENZ Q1 Earnings? - Defense World
Citigroup Increases LENZ Therapeutics (NASDAQ:LENZ) Price Target to $47.00 - MarketBeat
William Blair Issues Negative Outlook for LENZ Earnings - Defense World
LENZ Therapeutics (NASDAQ:LENZ) Price Target Raised to $47.00 - Defense World
Equities Analysts Offer Predictions for LENZ FY2026 Earnings - Defense World
What is HC Wainwright’s Estimate for LENZ Q1 Earnings? - Defense World
Lenz Therapeutics’ Earnings Call Highlights Positive Outlook - TipRanks
Promising Outlook for LENZ Therapeutics: Buy Rating Affirmed Amid Strong Market Position and Upcoming Product Launch - TipRanks
Brokerages Set LENZ Therapeutics, Inc. (NASDAQ:LENZ) PT at $35.40 - Defense World
Citi raises LENZ Therapeutics price target to $47, keeps Buy rating - Investing.com Australia
LENZ Therapeutics stock holds $38 target on FDA approval optimism By Investing.com - Investing.com Australia
LENZ Therapeutics stock holds $38 target on FDA approval optimism - Investing.com
Citi ups PT on LENZ Therapeutics on eye-drop approval confidence - TradingView
Lenz Therapeutics outlines Q4 2025 launch plans for LNZ100 amid FDA review progress - MSN
Earnings call transcript: LENZ Therapeutics Q4 2024 shows innovation drive - Investing.com India
Earnings call transcript: LENZ Therapeutics Q4 2024 shows innovation drive By Investing.com - Investing.com UK
LENZ Therapeutics, Inc. SEC 10-K Report - TradingView
LENZ THERAPEUTICS Earnings Results: $LENZ Reports Quarterly Earnings - Nasdaq
LENZ Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights - The Manila Times
LENZ Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent ... - The Bakersfield Californian
LENZ Therapeutics Secures FDA Decision Date with $209M War Chest for Presbyopia Drug Launch - StockTitan
LENZ Therapeutics (NASDAQ:LENZ) Now Covered by TD Cowen - Defense World
TD Cowen lifts LENZ Therapeutics stock to buy, sets $60 target - Investing.com Canada
TD Cowen lifts LENZ Therapeutics stock to buy, sets $60 target By Investing.com - Investing.com South Africa
TD Cowen Initiates LENZ Therapeutics at Buy With $60 Price Target -March 18, 2025 at 07:09 am EDT - Marketscreener.com
American Electric Power, Block and Lenz Therapeutics - TradingView
LENZ THERAPEUTICS Earnings Preview: Recent $LENZ Insider Trading, Hedge Fund Activity, and More - Nasdaq
LENZ Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights on March 19, 2025 - The Manila Times
LENZ Therapeutics Q4 Earnings: Key Updates Coming on Presbyopia Eye Drops - StockTitan
Rhumbline Advisers Boosts Stock Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
LENZ Therapeutics to Host Commercial Day on April 15, 2025 - The Manila Times
Will LENZ's Presbyopia Eye Drop Disrupt the Vision Care Market? Commercial Strategy Reveal Coming - StockTitan
Insiders Enjoy US$227k Return After Buying LENZ Therapeutics Stock - Simply Wall St
LENZ Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
LENZ Therapeutics to Present at Upcoming Investor Conferences in March 2025 - Nasdaq
Can LENZ's Novel Presbyopia Treatment Disrupt the $8B Eye Care Market? Key Investor Presentations Coming - StockTitan
Myopia And Presbyopia Eye Drops Market Future Business - openPR
LENZ Therapeutics (LENZ) to Release Quarterly Earnings on Wednesday - Defense World
LENZ Therapeutics Insiders Placed Bullish Bets Worth US$551.1k - Yahoo Finance UK
Citi maintains Buy on LENZ Therapeutics, target at $44 By Investing.com - Investing.com Canada
Citi maintains Buy on LENZ Therapeutics, target at $44 - Investing.com
Lenz Therapeutics Inc (LENZ) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.01%
자본화:
|
볼륨(24시간):